Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510996 | 1.00 | CASP3 (0.53) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL13253077 | 0.86 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL1739174 | 0.85 | MDM4 (0.54) | CASP3MDM4TP53 | |
| SCHEMBL10020438 | 0.85 | MDM4 (0.54) | CASP3MDM4TP53 | |
| SCHEMBL27129147 | 0.84 | MDM4 (0.49) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL27008576 | 0.84 | MDM4 (0.49) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL6517147 | 0.84 | CASP3 (0.47) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL10187000 | 0.84 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL13570148 | 0.84 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30112677 | 0.83 | CASP3 (0.55) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492225-B2 | Melanocyte-regulating peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-4532513-A1 | CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2025-04-09 | — | — | EP | disclosed |
| CN-119451974-A | Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens | 巴塞罗那全球健康研究所私人基金会 | 2025-02-14 | — | — | CN | disclosed |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-05 | — | — | US | disclosed |
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2024-03-14 | — | — | US | disclosed |
| WO-2023227771-A1 | CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2023-11-30 | — | — | WO | disclosed |
| EP-4271480-A1 | VEGF-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2023-11-08 | — | — | EP | disclosed |
| CN-116964074-A | Peptides that modulate VEGF | IDP研发制药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111263768-B | anticancer peptides | IDP研发制药有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3159352-B1 | STITCHED POLYPEPTIDES | HARVARD COLLEGE (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11440939-B2 | Anticancer peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-09-13 | — | — | US | disclosed |
| EP-4039698-A1 | PEPTIDES WITH ANTI-CANCER ACTIVITY | IDP Discovery Pharma, S.L. (ES) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022144401-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-07-07 | — | — | WO | disclosed |
| EP-4023295-A1 | VEGF-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2022-07-06 | — | — | EP | disclosed |
| EP-4007563-A1 | MELANOCYTE-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2022-06-08 | — | — | EP | disclosed |
| US-11352395-B2 | Anticancer peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-06-07 | — | — | US | disclosed |
| EP-3986914-A1 | CONSTRAINED PEPTIDES | TearSolutions, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114245800-A | Melanocyte regulatory peptides | IDP研发制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-22 | — | — | US | disclosed |
| CN-114206916-A | Restricted peptides | 缇尔索卢森公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492225-B2 | Melanocyte-regulating peptides | MC1R, MITF, MCHR1 | CASP3 4704/4885KMT2A 995/4885MDM4 450/4885 |
| US-11440939-B2 | Anticancer peptides | NGLY1, SLC1A5, SSTR5 | CASP3 1352/4885KMT2A 2923/4885MDM4 377/4885 |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | TP53, MDM2, MDM4 | CASP3 2615/4885KMT2A 3182/4885MDM4 3/4885 |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | IAPP, NGLY1, VIP | CASP3 1870/4885KMT2A 4628/4885MDM4 2200/4885 |
| US-11352395-B2 | Anticancer peptides | PNISR, NGLY1, SLC1A5 | CASP3 2512/4885KMT2A 1904/4885MDM4 265/4885 |
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | VEGFA, FLT4, FLT1 | CASP3 3795/4885KMT2A 3448/4885MDM4 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.